EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Computational Design and Structure-Guided Optimization of Anti-Osteopontin Monoclonal Antibodies at the Intersection of Obesity, Type 2 Diabetes, and Hepatocellular Carcinoma

Elahe Shams, Elham Rismani, Pedram Asadi-Sarabi, Mohsen Nasiri-Toosi, Reza Malekzadeh, Moustapha Hassan, Massoud Vosough

Journal of Genome Biotechnology and Genetics · 2026

DOI: 10.3390/jgbg1030019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Genome Biotechnology and Genetics, 2026. Verfasst von Elahe Shams und 6 weiteren Autor:innen. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, and obesity and type 2 diabetes (T2D) are recognized metabolic risk factors for its development. In this study, disease-associated gene lists for T2D and obesity were integrated with differentially expressed genes from the Cancer Genome Atlas Liver Hepatocellular Carcinoma cohort (TCGA-LIHC). Analysis of 371 primary HCC and 50 solid-tissue normal samples identified 2123 differentially expressed genes, including 715 upregulated and 1408 downregulated genes. The intersection of the 715 upregulated genes with 2055 T2D-associated and 1944 obesity-associated protein-coding genes identified 29 common candidates. Functional annotation identified 14 extracellular-region genes, which were evaluated using protein–protein interaction analysis and ranked using the maximal clique centrality algorithm. SPP1, encoding Osteopontin (OPN), was the highest-ranked candidate. SPP1 expression distinguished HCC from non-tumor tissues with an area under the receiver operating characteristic curve of 0.714 (95% confidence interval: 0.666–0.760). High SPP1 expression was associated with poorer overall survival, and continuous log2-transformed SPP1 expression remained independently associated with survival after adjustment for age, sex, and pathological stage. OPN was subsequently subjected to structural modeling, molecular dynamics simulation, B-cell epitope prediction, and the structure-guided optimization of anti-OPN monoclonal antibodies. Molecular docking and binding affinity analyses revealed that optimized mAbs exhibited predicted Kd values corresponding to approximately 10- to 650-fold stronger binding affinity and increased predicted hydrogen bonding at the interface. These findings support SPP1 as a promising immunotherapeutic target in metabolically driven HCC, warranting further experimental validation.

Zitieren

APA

Shams, E., Rismani, E., Asadi-Sarabi, P., Nasiri-Toosi, M., Malekzadeh, R., Hassan, M., & Vosough, M. (2026). Computational Design and Structure-Guided Optimization of Anti-Osteopontin Monoclonal Antibodies at the Intersection of Obesity, Type 2 Diabetes, and Hepatocellular Carcinoma. Journal of Genome Biotechnology and Genetics. https://doi.org/10.3390/jgbg1030019

Vancouver

Shams E, Rismani E, Asadi-Sarabi P, Nasiri-Toosi M, Malekzadeh R, Hassan M, et al. Computational Design and Structure-Guided Optimization of Anti-Osteopontin Monoclonal Antibodies at the Intersection of Obesity, Type 2 Diabetes, and Hepatocellular Carcinoma. Journal of Genome Biotechnology and Genetics. 2026. doi:10.3390/jgbg1030019

BibTeX
@article{Shams2026,
  author = {Shams, Elahe and Rismani, Elham and Asadi-Sarabi, Pedram and Nasiri-Toosi, Mohsen and Malekzadeh, Reza and Hassan, Moustapha and Vosough, Massoud},
  title = {Computational Design and Structure-Guided Optimization of Anti-Osteopontin Monoclonal Antibodies at the Intersection of Obesity, Type 2 Diabetes, and Hepatocellular Carcinoma},
  journal = {Journal of Genome Biotechnology and Genetics},
  year = {2026},
  doi = {10.3390/jgbg1030019}
}
Kostenlos starten →